Article info

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

Authors

  1. Correspondence to Dr Josef S Smolen, Medical University of Vienna, 1090 Wien, Austria; josef.smolen{at}meduniwien.ac.at
View Full Text

Citation

Smolen JS, Siebert S, Korotaeva TV, et al
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

Publication history

  • Received March 2, 2021
  • Accepted May 27, 2021
  • First published June 23, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.